Case 1 MPB
Ms MPB is a white woman who last year, when she was 27-years-old, went to our Vascular Emergency room for a pain in the left calf. The week before she had a minor road accident when she was driving her motorcycle, with a trauma of the left leg. Her personal history showed no important diseases or previous venous thromboembolism (VTE). At physical examination the BMI was 20.7; there was no edema in the symptomatic leg, but the pain, moderate at rest, increased at gentle palpation of calf muscles. One point was attributed by the Wells score (interpreted as moderate risk)
1 . Blood was sampled for D-dimer testing (STA Liatest D-dimer; Diagnostica Stago, Asnieres, France) scoring just above the upper normal limit (540 ng/ml; nv= < 500 ng/ml). An ultrasound (US) examination was then performed, showing isolated thrombus in posterior tibial veins. A full anticoagulant dose of low molecular weight heparin (LMWH) was prescribed for ten days, followed by half the daily dose to complete one month of treatment; a below-knee elastic stocking (class II) was recommended. At the end of treatment no symptoms were reported and no US signs of thrombus seen.
Case 2 RP
Mr RP is a 46-year-old white man who in July this year referred to our unit for a pain in the right calf that appeared 5 days before. The day before the visit, ankle and calf swelling also appeared with the pain so his doctor advised him to come to our outpatient service. His personal history showed no important diseases, no previous thrombotic event, no predisposing triggering factors. At physical examination, the BMI was 27.7; the right calf measured 2 cm > the contralateral; the pain was present at rest, increasing at palpation. Two points were attributed by the Wells score (moderate risk). D-dimer test was clearly abnormal (835 ng/ml; normal values = < 500 ng/ml). At US examination thrombi were detected in one gastrocnemious vein and in one peroneal vein. A full anticoagulant treatment with LMWH was started together with warfarin administration, with a program of 3 months anticoagulation (INR 2.0-3.0); a below-knee elastic stocking (class II) was also prescribed. The treatment is still under way and the patient, who is feeling well, is waiting to finish anticoagulation to repeat US examination.
While both patients described above had thrombosis limited to infra-popliteal veins of the lower limbs (isolated distal deep vein thrombosis, IDDVT), our therapeutic approach was different in the two cases. Though IDDVTs occur frequently, their clinical significance is still unclear; major disparities exist between countries (and between professionals within the same country) over their
For personal use only. on December 29, 2017. by guest www.bloodjournal.org From management both regarding how (and if) to diagnose and how to treat. Indeed, IDDVT is presently one of the most debated issues in the field of venous thromboembolism (VTE) on account of the scarcity of scientific evidence available In this manuscript, I will briefly review what we know of the issue, focusing especially on the clinical risk in patients with IDDVT and proposed treatments, and outline my current therapeutic approach to such patients.
The "distal" or "calf" deep veins
The word "distal" refers to the deep veins below the knee. Though anatomical variability is often the case, these veins include the paired peroneal, posterior tibial and anterior tibial veins that accompany the corresponding arteries of the lower leg (see Figure 1 ). These paired veins unify proximally into confluent segments which form the trifurcation area before joining to become the popliteal vein. Since the confluent segments are easily identified at US examination of knee hollow, it is now standard to classify the trifurcation area as proximal.
The calf deep veins also include two groups of muscle veins: the soleal muscle veins, that are connected with the posterior tibial or peroneal veins; and the gastrocnemius muscle veins that drain into the popliteal vein. Though some authors [2] [3] [4] claim that isolated calf muscle vein thrombosis (ICMVT) should be distinguished from IDDVT (thrombosis in the paired veins), most clinical contributions consider these anatomically distinct veins as a whole (and refer to them as IDDVT).
Diagnosis of proximal and distal DVT
Venous US investigation, based on compression of veins (CUS, compression ultrasonography), helped by color flow duplex imaging, is nowadays the method almost exclusively adopted for diagnosing DVT in routine clinical practice. However, two CUS strategies are currently performed in subjects with suspected leg DVT:
1) Serial CUS examination of only proximal veins; this strategy is based on the premise that distal DVT may result in risk of complications and deserve treatment only if and when it expands to involve more proximal veins, an eventuality expected to occur in a minority of cases and within one/two weeks from initial symptoms. For this reason, CUS should be repeated in patients at risk during this interval period to detect possible extension of calf DVT to popliteal or more proximal veins. Obviously, this strategy does not look for and does not detect IDDVTs.
2) Complete CUS examination of all deep veins examined in a single procedure able to detect all
IDDVTs. This procedure is less simple than the former and requires more skilful, specially trained operators; a significantly lower sensitivity of CUS for IDDVT than for proximal DVT has been Both the diagnostic procedures (serial or complete CUS examinations) have been found to be effective and safe and are accepted in clinical practice 9,10 .
Epidemiology
A series of factors account for the large variation of IDDVT prevalence in the literature. First, the diagnostic method and procedure adopted: venography, or US. Second, the different clinical settings: asymptomatic patients examined for DVT in clinical studies on surgical or medical patients, or in-or out-patients examined for suspected DVT or pulmonary embolism (PE), or after diagnosis of PE, searching for a possible embolic source.
In studies investigating deep veins in the whole leg to assess the incidence of DVT in situations at risk, IDDVT was the most prevalent finding in asymptomatic patients. Interestingly , in the few studies comparing results obtained with venography or US in populations at risk, the prevalence of IDDVT was higher in US
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. In patients examined for suspected PE or leg DVT, the prevalence of IDDVT ranged between 7 to 11% in cases with suspected PE and 4 to 15% in suspected DVT, In conclusion, it should be recognized that, due to the scarcity of prospective, blind, non intervention studies, both the natural history of IDDVT and its clinical relevance are still not clearly understood. In general, however, it can be said that the proximal extension of IDDVT, while at rates much lower than previously reported, is not rare, and the disease -with or without extension -is not always free from acute and late complications. Many studies reviewed by Righini et al. 21 and two more recent randomized studies in symptomatic patients 50,51 compared the results of the two different diagnostic strategies -serial proximal CUS or single whole leg vein examination, with only the latter being able to diagnose and treat IDDVT.
They consistently found that 3-month thromboembolic risk did not differ in the two diagnostic approaches, indicating that it is not indispensable to diagnose and treat IDDVTs. We only partially agree with that conclusion, especially on the basis of the results of our recent CALTHRO study, which to my knowledge is the only one to date to have left patients untreated after calf DVT diagnosis and hence able to provide insights into the natural history of the disease. In fact, while it was shown that the rate of proximal extension at one week of diagnosed but untreated IDDVT was much lower than expected (3.1%), the rate of complications at three months was nevertheless significantly higher in subjects with vs without calf DVT (7.8% vs. 0.8%, p= 0.003), though the difference was not very significant after excluding two subjects with proximally extending calf DVT picked at the 2nd serial CUS (4.7% vs. 0.8%; p=0.049) 23 . These data seem to support the view that while most IDDVTs are self limiting and inconsequential for patients, a few are not free of risk and warrant diagnosis and treatment. The problem is that it is not easy to single out the symptomatic patients at higher risk of complication.
1 0
Personal views
In what follows I would like to give some personal opinions on how my coworkers and I select diagnostic procedures in patients with suspected DVT and what sort of treatment we offer those with diagnosed IDDVT.
1) I find it hard to agree with what was suggested by the ACCP guideline regarding diagnosis and treatment of IDDVT: "If isolated distal DVT is detected on whole-leg US, we suggest serial testing to rule out proximal extension over treatment (Grade 2C)"
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. It is extremely difficult in every day clinical practice, if not impossible -at least in my country -, to diagnose and inform the patient (and his GP) that he has venous thrombosis, albeit limited to a calf vein, without giving him appropriate therapy. First, the patient is already symptomatic and referred to the emergency vascular room with symptoms we ascribe to the presence of thrombosis; he expects to receive some kind of treatment to improve such symptoms. Second, after being informed of the presence of thrombosis the patient should also be informed of the risks associated with this condition: the possible extension of the thrombosis and -though rare-occurrence of PE (with or without extension). Imparting this information without giving any treatment would cause anxiety in the patient and would disappoint the doctor, who would probably in the meantime administer some therapy (in most cases heparin or derivatives). We know that this kind of treatment, if not given at therapeutic doses, is not fully curative and may interfere with serial US testing, since thrombus proximal extension can only be delayed but not completely averted.
It should be recognized, however, that ACCP guideline recommendations may have also been prompted by economic reasons (to limit the cost of anticoagulant treatment, that in some cases may even be unnecessary), and above all by a need to improve the lifestyle of patients which is inevitably compromised by an anticoagulant course. I am therefore convinced that after IDDVT is diagnosed proper treatment should be given.
The main problem is the best diagnostic procedure to adopt in symptomatic outpatients since this will decide the number of IDDVTs diagnosed. Obviously, when whole-leg examination is used in all symptomatic patients a consistent number of IDDVTs are diagnosed and 6% to 14% more thromboses can be expected 50,51 .
We believe that a better solution is to select a single diagnostic strategy based first on exclusion of proximal DVT in all symptomatic outpatients by using CUS, and then extending US to calf veins only in those patients deemed to be at higher risk on the basis of probability scores and/or risk markers, such as increased D-dimer levels ( Figure 2 ). ], and we will have to wait for its results to know if it is effective and safe.
2) Heparin, LMWH or fondaparinux can be used for acute treatment of patients with IDDVT; they can be overlapped with VKAs, preferably in 3-month treatment periods, or used alone, in special conditions (such as presence of cancer) or when the foreseen period of treatment is shorter. The cost of the drugs differs widely from one country to another, and is often expensive (even after the introduction of generic enoxaparin, where available). The final choice may, therefore, be influenced by the cost-effectiveness of the drugs in relation to local marketing conditions that can make a drug cheaper than others.
3) Several phase III clinical studies have confirmed the efficacy and safety of new oral anticoagulant drugs [direct thrombin (dabigatran) or factor Xa inhibitors (rivaroxaban, apixaban, edoxaban)] for acute -monotherapy or after initial treatment with parenteral anticoagulants -and extended VTE treatment. Unfortunately, only proximal DVT has been included in these trials and therefore no data is currently available on the clinical outcome of IDDVTs treated with these drugs. It may be surmised however that, when and where licensed and available in clinical practice for treatment of DVT, these new anticoagulants will also be used in IDDVT for a series of reasons: a single oral drug for the whole treatment (no need for initial parenteral anticoagulants, for some of these drugs), fixed dose, no need for routine laboratory tests. In countries where one or more of these drugs is approved for treatment of symptomatic DVT/PE, it is not stipulated that DVT must be proximal and so their use for symptomatic IDDVT is not considered "off- parenteral anticoagulation for 4-6 weeks, or for initial anticoagulation followed by warfarin for 3 months; the necessary doses and duration of treatment remain however to be assessed in patients with secondary or unprovoked IDDVT. Studies specifically devoted to use of these drugs in patients with IDDVTs are needed, to assess their efficacy and safety in treatment of these patients and to limit as much as possible the burden for patients while keeping costs for health services to a necessary minimum.
How I treat IDDVT (Figure 2)
Once diagnosed in symptomatic outpatients all IDDVTs should receive anticoagulant treatment. In our institution my coworkers and I regulate the type, dose, and duration of treatment depending on a series of factors: history of VTE, nature of the event (idiopathic or secondary), extension of thrombosis, presence of important predisposing diseases. All these conditions, risk factors for extension and potential complications, are similar to those mentioned by the authors of the last ACCP guidelines 43 , the only difference being that they suggest using the presence or absence of these factors as criterion for deciding whether to give anticoagulation or to proceed with serial imaging alone. They recommend using the same approach (for duration and intensity) as in patients with acute proximal DVT. In contrast, our approach is based on the use of these conditions as criteria for regulating the type and duration of anticoagulation, since we believe there is evidence for shorter anticoagulation (and probably even less intense) in many IDDVTs 26,29,57 .
Our usual practical therapeutic approach to outpatients with IDDVT is first to exclude contraindications for anticoagulant treatment -such as major or non-major but clinically relevant bleeds or serious bleeding diseases, marked thrombocytopenia, or renal insufficiency -and then to start the following treatment.
1) In the presence of one of the conditions listed in Table 1 still deemed necessary a prophylactic LMWH dose is administered.
2) In patients with conditions shown in Table 1 part B, we start with a full dose of one parenteral anticoagulant, usually LMWH, for the first 7 to 10 days and then we lower the dose to 50% for the next days to cover 1 month of therapy.
3) All patients are recommended to wear a below knee class II elastic stocking in the symptomatic leg, a measure reported to be highly curative in itself 23, 4 . The patients receive a US examination at the end of anticoagulation to assess IDDVT evolution, to have a basal picture of deep calf veins in case new symptoms/signs occur suggesting possible DVT recurrence.
The treatment approach in cases 1 and 2 was different because in case 1 a trigger factor was present (a trauma in the calf, albeit minor), only one deep vein was affected, there was no immobilization or walking impairment and so we gave the treatment described in paragraph 2 above. In contrast, in case 2 the event was idiopathic, more than one deep vein was involved, symptoms were relatively important, and walking and mobilization was at least in part hampered, which led us to prescribe complete anticoagulation, starting with therapeutic LMWH doses overlapped with VKAs for a duration of three months.
Finally, I expect the very recent availability of direct oral anticoagulants for acute treatment of DVT (at the moment only rivaroxaban in my country for this indication) will shortly prompt a change in our therapeutic approach to patients with IDDVT. As I said above, monotherapy is highly preferable to parenteral anticoagulation followed or not by a 3 month course of warfarin.
However, I believe the initial and long-term doses and duration of treatment in these patients,
issues not covered at all by phase III clinical trials, remain to be assessed. I would therefore prefer to offer these patients a treatment within studies specifically devoted to assess use of these drugs in this particular type of venous thrombosis.
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• Table 1 Presence of conditions in part A of Table 1 4-6 weeks therapy with LMWH (possibly NOAC) 3 months standard anticoagulation (possibly NOAC)
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